ARWR
Fiscal year ends September Quarters are offset from the calendar — Q1 is Oct–Dec

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing disease-causing genes using RNA interference (RNAi) technology. The company utilizes its proprietary Targeted RNAi Molecule (TRiM) platform to enable tissue-specific delivery of small interfering RNAs (siRNAs) to various cell types. Its approved product, REDEMPLO (plozasiran), is indicated as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome. The company’s pipeline includes drug candidates for severe hypertriglyceridemia, homozygous familial hypercholesterolemia, mixed hyperlipidemia, and conditions affecting the cardiometabolic, pulmonary, liver, and neuromuscular systems. Arrowhead has entered into license and collaboration agreements with Sarepta Therapeutics, Amgen, Takeda, Glaxosmithkline, Novartis, and Sanofi to expand the reach of its technology and support wholly-owned programs.

Summarised from the company's own disclosures, fiscal year ended Nov 2025

Industry Biotechnology Homepage arrowheadpharma.com
Sector Healthcare IR page ir.arrowheadpharma.com
Tags
rna interference, sirna therapeutics, gene silencing, cardiometabolic diseases, hypertriglyceridemia, familial chylomicronemia syndrome, hypercholesterolemia, pulmonary diseases, liver diseases, neuromuscular diseases, targeted drug delivery, REDEMPLO, plozasiran, ARO-APOC3, zodasiran, ARO-ANG3, ARO-DIMER-PA, TRiM, Sarepta Therapeutics, Amgen, Takeda, Glaxosmithkline, Novartis, Sanofi
Press page arrowheadpharma.com/en-us/newsroom

Metrics

Valuation  
Market cap $ 9.247B
Market cap (USD) $ 9.247B
P/E -12.81
PEG —
P/BV 183.80
P/S 20.51
P/OCF -34.00
P/FCF -32.57
Dividend yield —
Turnover / mcap —
Returns  
ROE -280.5%
ROI -700.4%
ROIC -513.0%
Profit margin -160.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 134
Quality score -77.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Revenue 450.817M 829.448M 3.551M 240.735M 243.231M 138.287M 87.992M 168.796M 16.142M 31.408M 158.333K 382K 175K 290.266K 146.875K 296.139K — — — — —
Net profit -724.206M -1.631M -599.493M -205.275M -176.063M -140.848M -84.553M 67.975M -54.45M -34.38M -81.723M -91.941M -58.63M -31.143M -21.126M -3.129M -5.774M — — — —
Free cash flow -283.944M 156.886M -604.32M -330.627M -188.908M 147.657M -107.343M 161.034M -48.645M -31.857M -68.288M -67.678M -37.134M -19.33M -15.82M -7.666M — — — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Share price 65.45 34.49 19.37 26.87 33.05 62.43 43.06 28.18 19.17 4.33 7.35 8.01 15.02 — — 0.89 0.89 — 3.86 5 4.88
Price performance 12m 0.9 0.78 -0.28 -0.19 -0.47 0.45 0.53 0.47 3.43 -0.41 -0.08 -0.47 — — — 0 — — -0.23 0.02 —

Filed figures

Figure Sep 2017 Sep 2018 Sep 2019 Sep 2020 Sep 2021 Sep 2022 Sep 2023 Sep 2024 Sep 2025 Sep 2026
Balance sheet detail
Trade receivables (USD) 67,797 327,375 661,361 845,673 10.3M 1.41M 0.00 0.00 6.82M 9.93M
↳ YoY growth -9.6% +382.9% +102.0% +27.9% +1,112.6% -86.3% -100.0% +45.6%
↳ 5y CAGR +48.5% +34.3% +167.4% +83.5% +51.8% -0.6%
Lease liabilities (USD) — — — 21.1M 25.5M 81.6M 115M 117M 111M 121M
Cash and deposits (USD) 24.8M 30.1M 222M 144M 184M 108M 111M 103M 227M 62.7M
Intangible assets (USD) 20.5M 18.8M 17.1M 15.4M 13.7M 12M 10.3M 8.56M 6.86M 5.16M
Right-of-use assets (USD) — — — 16.1M 17.3M 58.3M 45.3M 45.3M 43.9M 58.3M
Cash flow detail
Operating cash flow (USD) -23.9M -47.2M 173M -95.4M 171M -136M -154M -463M 180M -272M
Purchases of property, plant and equipment (USD) -7.92M -1.42M -12M -12M -23.6M -52.8M -177M -141M -22.7M -12M
Change in receivables (cash effect) (USD) 7,203 -259,578 -333,986 -184,312 -9.41M 8.85M 1.41M 0.00 -57M -3.29M
Change in inventories (cash effect) (USD) — — — — — — — 0.00 0.00 -9.08M
Change in payables (cash effect) (USD) -3.51M -1.27M 4.84M -821,012 2.63M -6.59M 33M -5.54M 6.29M 12.5M
Interest paid (cash effect) (USD) -187,647 -173,381 -27,437 0.00 0.00 0.00 0.00 0.00 -19,000 0.00
Income taxes paid (cash effect) (USD) -2,400 -2,400 -302,400 -103,437 2,000 2,000 0.00 3.74M -814,000 -21.6M
Share-based compensation (USD) 7.89M 8.45M 12.4M 43.4M 76.7M 121M 78.1M 74M 63.4M 68.1M
Operating cash flow before change in receivables (USD) -23.9M -47M 173M -95.2M 181M -145M -155M -463M 237M -269M
Free cash flow (OCF - PPE - intangibles) (USD) -31.9M -48.6M 161M -107M 148M -189M -331M -604M 157M -284M
Income detail
Research and development expense (USD) 31.7M 53M 81M 129M 206M 297M 353M 506M 607M 739M
↳ 5y CAGR +42.5% +43.5% +28.5% +22.2% +37.8% +56.5% +46.1% +44.2% +36.3% +29.1%
Total comprehensive income (USD) -34.4M -54.5M 67.6M -84.1M -141M -177M -212M -602M 31.8M -730M
Comprehensive income to owners (USD) -34.4M -54.5M 67.6M -84.1M -141M — — -592M 62,000 -738M
Reported Dec 12, 2017 Dec 11, 2018 Nov 25, 2019 Nov 28, 2022 Nov 28, 2022 Nov 28, 2022 Nov 29, 2023 Nov 12, 2026 Nov 12, 2026 Nov 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Conference Call and Webcast Today, November 12, 2026, at 4:30 p.m. ET

PASADENA, Calif., Nov. 12, 2026 — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting a conference call today, November 12, 2026, at 4:30 p.m. ET to discuss the results.

“Arrowhead has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, there is now a company that is beginning to translate promise into real patient outcomes and the potential for durable shareholder value growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We are building a commercial business around REDEMPLO®, we delivered pivotal data we believe is needed to pursue a much larger market in severe hypertriglyceridemia we have recently submitted an sNDA to the U.S. FDA, and we have demonstrated new capabilities that substantially expand what our RNAi platform can do.

Home /

Newsroom

/

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

PDF Version

- Existing $400 million facility prepaid at a $68 million discount to the contractual minimum repayment amount

- New $400 million term loan priced at SOFR plus 5.50%

- Debt has no scheduled amortization payments or required sweeps during the term prior to the Maturity Date of November 2, 2031

PASADENA, Calif.--(BUSINESS WIRE)--Nov. 4, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases financial and operational flexibility. The transaction retires Arrowhead’s existing $400 million Sixth Street facility at a $68 million discount to the contractual minimum repayment amount and establishes a new $400 million Sixth Street senior secured term loan facility bearing interest at the Secured Overnight Financing Rate (SOFR) plus 5.50%.

“This transaction is an important step in aligning our capital structure with the company Arrowhead has become. By reducing the amount required to retire our existing facility and lowering our ongoing borrowing costs, we are improving the economics of our financing for shareholders,” said Daniel Apel, Chief Financial Officer of Arrowhead. “As we build the REDEMPLO® business and advance our pipeline, we are securing financing terms that more closely reflect our profile as a commercial-stage biopharmaceutical company. Sixth Street’s continued support reflects its confidence in our business and the opportunities ahead.”

Transaction Highlights

  • Lower borrowing costs. The new facility carries an interest rate of SOFR plus 5.50%, compared to an annual rate of 15% in the retired facility.
  • Reduced minimum prepayment multiple. Negotiated a $68 million discount on the contractual prepayment amount on the retired facility, which originally carried a minimum 2x multiple on invested capital (MOIC) if paid in full by August 2028 and escalated to a 2.5x MOIC thereafter.
  • Reduced contractual sweep obligation. The retired facility required Arrowhead to partially repay loans under the credit facility with a sweep of a portion of the proceeds from certain transactions, such as the future collection of upfront payments, milestones, and royalties from partnerships and collaborations, and commercial revenue by Arrowhead. The new facility eliminates these required prepayments or sweeps and reduces the prepayment premiums associated with paying off the facility early.
  • Greater strategic, financial, and operational flexibility. The new facility significantly improves Arrowhead’s ability to independently engage in strategic, financial, and operational activities.
  • Extended maturity enhancing near-term liquidity. The new facility matures in November 2031.

“Arrowhead has made significant progress in translating its RNAi platform into a commercial business with substantial growth opportunities,” said Jeff Pootoolal, Partner, and Michael Reslinski, Managing Director at Sixth Street. “We are pleased to continue our relationship through a new financing structure that recognizes that progress and supports the company’s next phase of growth.”

The new senior secured credit facility matures on November 2, 2031, and bears interest at an annual rate equal to the 3-month SOFR plus 5.50%, with certain additional fees and prepayment terms. There are no scheduled amortization payments during the term of the facility, with all principal due on the maturity date. Arrowhead is not required to prepay or sweep any proceeds from certain transactions, such as the future collection of upfront payments, milestones, and royalties from partnerships and collaborations, and commercial revenue. Arrowhead may prepay all or any portion of the loans at any time at a prespecified premium, not to exceed 2%, if prepaid more than 18 months after the Closing Date, plus a make-whole premium for any prepayments made prior to May 2, 2028. All obligations will be secured on a first-priority basis, subject to certain exceptions, by security interests in substantially all assets of the company. Please refer to Arrowhead’s 8-K for more information.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.

Home /

Newsroom

/

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

PDF Version

PASADENA, Calif.--(BUSINESS WIRE)--Nov. 3, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its financial results for the 2026 fiscal year ended September 30, 2026.

Webcast and Conference Call Details

Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.

For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI7f86d910b33a4c78a5bdc6525130794f . Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.

Prompts

Arrowhead Pharmaceuticals, Inc. (ticker ARWR), listed in United States.

Company History

Date Change Detail
Apr 7, 2016 Renamed ARROWHEAD RESEARCH CORP → ARROWHEAD PHARMACEUTICALS, INC.
Feb 3, 2004 Renamed INTERACTIVE GROUP INC → ARROWHEAD RESEARCH CORP

ETFs Holding Arrowhead Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
ADPV 4.99% 105,093 $ 8.896M Jul 31, 2026
FRTY 2.70% 51,006 $ 4.157M Jun 30, 2026
JSMD 0.80% 99,071 $ 8.386M Jul 31, 2026
HRTS 0.78% 5,263 $ 433.619K Aug 31, 2026
FLDZ 0.53% 265 $ 21.6K Jun 30, 2026
PSC 0.45% 129,376 $ 10.545M Jun 30, 2026
RUSC 0.35% 3,395 $ 276.726K Jun 30, 2026
FESM 0.35% 246,832 $ 20.119M Jun 30, 2026
CLSE short -0.33% -36,550 $ -3.011M Aug 31, 2026
MKTN short -0.27% -3,603 $ -293.681K Jun 30, 2026
VFMO 0.24% 55,454 $ 4.569M Aug 31, 2026
JMEE 0.15% 101,303 $ 4.355M Nov 17, 2026
SCDS 0.14% 288 $ 12.381K Nov 17, 2026
SMDX 0.13% 3,771 $ 166.716K Nov 17, 2026
FSML 0.12% 1,865 $ 152.016K Jun 30, 2026
TMSL 0.10% 33,383 $ 2.721M Jun 30, 2026
FSEG 0.10% 70 $ 5,705.70 Jun 30, 2026
REMC 0.07% 31 $ 2,526.81 Jun 30, 2026
MSSM 0.07% 5,878 $ 484.288K Aug 31, 2026
IALT short -0.05% -82,358 $ -3.641M Nov 16, 2026
FTLS 0.05% 28,590 $ 0.00 Nov 16, 2026
AVIE 0.04% 165 $ 7,294.65 Nov 16, 2026
FMDE 0.03% 28,735 $ 2.342M Jun 30, 2026
DFAS 0.02% 115,811 $ 5.46M Nov 12, 2026
DFAC 0.01% 165,626 $ 7.809M Nov 12, 2026
DFSU 0.01% 3,408 $ 160.687K Nov 12, 2026
DCOR 0.00% 10,755 $ 507.098K Nov 12, 2026